Inovio Pharmaceuticals (INO) Presents Positive dBiTE Data At AACR - Maxim

Maxim Group analyst Jason McCarthy reiterated a Buy rating and $8.00 price target on Inovio Pharmaceuticals (NASDAQ: INO) after the company and its collaborators from The Wistar Institute presented positive preclinical data from its novel dBiTE (DNA-Encoded Bi-specific T Cell Engager) program at the American Association for Cancer Research (AACR) annual meeting.

Regarding CD19 dBiTE, the analyst stated "In vitro work demonstrated that the construct is specific
to B-cell specific CD19 expressing cells". Regarding HER2 dBiTE the analyst stated "In a mouse model of ovarian cancer, a single dose of the construct elicited high levels of corresponding BiTE antibody in mice for 4 months, resulting in tumor rejection. Why is this important? Conventional BiTEs have a half-life of only ~2 hours, which requires frequent infusions that produce high levels of infusion-associated adverse events".

For an analyst ratings summary and ratings history on Inovio Pharmaceuticals click here. For more ratings news on Inovio Pharmaceuticals click here.

Shares of Inovio Pharmaceuticals closed at $3.70 yesterday.

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• Intuitive Surgical (ISRG) PT Raised to $435 at Piper Sandler
• Synovus Financial (SNV) PT Lowered to $42 at Piper Sandler